Ministry of Science, Technology and Productive Innovation, Advisory Commission on Cellular Therapies and Regenerative Medicine , Buenos Aires, Argentina .
Stem Cells Dev. 2013 Dec;22 Suppl 1:40-3. doi: 10.1089/scd.2013.0431.
Argentina has a significant number of researchers in public and private institutions conducting research in regenerative medicine and stem cells. There is not specific legislation in this area; however, the National Ministry of Health has issued regulations under the scope of the Transplant Act and the Medicines Act. Alongside the groups doing research, it is possible to find professionals offering experimental stem cell therapies to patients. These professionals take refuge in the term "medical practice" and sell experimental treatment to patients with no guarantee of safety and security given that they were not tested in clinical research. These practices offered to patients in a scheme, apparently legal, are generating an important number of judicial actions requesting the payment of said treatments. The decisions of the courts ordering payment in most cases are generating a transfer of funds from patients, social welfare systems, and the state to medical centers offering stem cell experimental therapies. This article describes the current regulations as well as the course of action to solve the emerging problems of these new technologies at legislative level.
阿根廷有大量的研究人员在公共和私营机构中从事再生医学和干细胞研究。该领域没有专门的立法；然而，国家卫生部已经在《移植法》和《药品法》的范围内发布了法规。除了从事研究的团体之外，还可以发现一些专业人员为患者提供实验性干细胞疗法。这些专业人员利用“医疗实践”一词作为掩护，向患者出售未经临床研究测试的实验性治疗，而没有任何安全性和保障性的保证。这些以看似合法的方案提供给患者的治疗方案，正在引发大量司法诉讼，要求支付这些治疗费用。在大多数情况下，法院作出支付判决的决定，导致患者、社会福利系统和国家的资金转移到提供干细胞实验性治疗的医疗中心。本文描述了当前的法规，以及在立法层面上解决这些新技术出现的问题的行动方案。
